Determinants of Re Bleeding and Mortality in Cirrhotic Patients after Variceal Bleeding


Approximately 50% of patients with cirrhosis have gastroesophageal varices and variceal bleeding (VB) from varices occurs in 30% of those patients. The rate of bleeding with known varices is 12 to 15% per year and VB is only 5–11% of all gastrointestinal bleeding1,2 but it is 60–65% of bleeding episodes in cirrhotic patients. Baveno VI consensus conference3 recommended following hemodynamic resuscitation, endoscopic variceal ligation or tissue adhesive should be undergone within 12h of presentation and vasoactive drugs should be started as soon as possible, before endoscopy. Antibiotic prophylaxis is an integral part of therapy for cirrhotic patients presenting with upper gastrointestinal bleeding but it may be voided in CTP class A patients as very low risk of bacterial infection and mortality. Vasoactive drugs (terlipressin, somatostatin, octreotide) should be used in combination with endoscopic therapy to improve outcomes following variceal bleeding.4 VB is a major cause of mortality and morbidity in cirrhotic patients.5,6The risk of re-bleeding within 1 year is approximately 60%.7 Mortality rate from each episode of VB is approximately 15 to 20%8,9 in the past and 10 20% at 6 weeks mortality in the previous study.

 Thus, it is extremely important that patients who survive an initial VB start on prophylactic therapy to prevent future bleedings. Several factors may increase the risk of bleeding such as the size of the varices, presence at endoscopy of red wale markings, the severity of liver disease and active alcohol use.11 Several factors have been identified as predictors of mortality after VB, including bacterial infection, hepatic venous pressure gradient (HVPG) >20 mmHg measured shortly after admission, active bleeding at initial endoscopy, severity of initial bleeding, presence of portal vein thrombosis(PVT), hepatocellular carcinoma (HCC), alcoholic liver disease, early re-bleeding, serum bilirubin and albumin levels, Child-Turcotte-Pugh (CTP) class B or C, and Model for End-stage Liver Disease (MELD) score.12-14 With our hospital data-base, we will analyse patient characters (age, sex, aetiology of cirrhosis, CTP score, MELD score, portal vein thrombosis, ascites), association with HCC and PVT; and different characters of alcoholic cirrhotic patients. We evaluate clinical outcomes including non-controlled bleeding, re-bleeding and mortality at day-5, week-6 and 1-year. Moreover, we identify the risk factors of re-bleeding and mortality of cirrhotic patients after initial variceal bleeding.

https://www.stephypublishers.com/sojcem/pdf/SOJCEM.MS.ID.000515.pdf

Comments

Popular posts from this blog